Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
It is imperative that primary care clinicians have a thorough understanding of insomnia, because they are often the first point of contact for patients who seek assistance when they have difficulty sleeping. Insomnia may appear with different presentations: sleep onset, sleep maintenances, sleep offset, nonrestorative sleep, or a combination of these symptoms. Untreated symptoms result in clinically significant distress or impairment in social, occupational, or other important areas of following-day functionality. Physicians, pharmacists, and other clinicians should be aware of the conditions that contribute to, are antecedent to, and associated with insomnia. These pathophysiological conditions include advanced age; female gender; respiratory, gastrointestinal, vascular, and rheumatologic pain syndromes; and other conditions such as depression and/or anxiety. Additional health factors contributing to insomnia include chronic pain, stressors, grief reaction, pharmacotherapeutic side effects, lifestyle contributors such as social/recreational drugs, phytopharmaceuticals, and ethanol use. The pharmacotherapy focus in this article is a modified-release formulation of the BZ1 (omega1) receptor agonist zolpidem, zolpidem extended-release. Pharmacokinetic, pharmacodynamic, and safety studies that compare 12.5 mg zolpidem extended-release (Ambien CRtrade markCIV) and 10 mg original zolpidem were initially conducted in healthy volunteers to assess the potential for an improved clinical profile. Zolpidem extended-release (12.5 mg and 6.25 mg extended-release dosage forms) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Zolpidem extended-release is devoid of any short-term use limitation and can be prescribed for the duration of medical necessity. The modified-release zolpidem is a two-layer tablet with a biphasic release profile, releasing the first layer immediately, whereas the second layer is released at a slower rate. Plasma concentrations are maintained for a longer period of time versus the immediate-release zolpidem formulation. Pharmacokinetic analysis has also demonstrated that the time to maximum concentration (tmax) and terminal elimination half-life (t1/2) of 12.5 mg zolpidem extended-release are similar to those of 10 mg zolpidem indicating a similar rapid onset of action and an elimination profile that reduced the risk of next-day decrements in performance. Zolpidem's CYP 450 hepatic metabolism uses as a substrate CYP3A4 (major) and 1A2, 2C9, 2C19, and 2D6 as minor pathways. Zolpidem extended-release dosage forms diminish sleep latency, number of awakenings, and wakefulness after sleep onset and augments total time asleep.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young Adults
Breslau, N., Roth, T., Rosenthal, L., & Andreski, P. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00188-3 · Cited by 1,831
Insomnia and Its Treatment: Prevalence and Correlates
Mellinger, G. D. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790260019002 · Cited by 1,071
Sleep and depression--results from psychobiological studies: an overview
Riemann, D., Berger, M., & Voderholzer, U. (2001) · Biological Psychology · doi:10.1016/s0301-0511(01)00090-4 · Cited by 653
Disturbed Sleep and Its Relationship to Alcohol Use
Stein, M. D., & Friedmann, P. D. (2006) · Substance Abuse · doi:10.1300/j465v26n01_01 · Cited by 288
Insomnia and health problems in Canadians
Sutton, D. A., Moldofsky, H., & Badley, E. M. (2001) · Sleep · doi:10.1093/sleep/24.6.665 · Cited by 207
Insomnia and complicated grief symptoms in bereaved college students
Hardison, H. G., Neimeyer, R. A., & Lichstein, K. L. (2005) · Behavioral Sleep Medicine · doi:10.1207/s15402010bsm0302_4 · Cited by 206
Cited by
Greenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
The clinical and forensic toxicology of Z-drugs
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0292-0 · Cited by 230
In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0294-y · Cited by 177
Hypnotics in Insomnia: The Experience of Zolpidem
MacFarlane, J., Morin, C. M., & Montplaisir, J. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.017 · Cited by 94
Shih, H.-I., Lin, C.-C., Tu, Y.-F., Chang, C.-M., Hsu, H.-C., Chi, C.-H., & Kao, C.-H. (2015) · Medicine · doi:10.1097/md.0000000000000809 · Cited by 55
Metadata
- Authors
- Barkin, R. L.
- Venue
- American Journal of Therapeutics
- Published
- 2007-05
- Volume
- 14
- Issue
- 3
- Pages
- 299-305
- ISSN
- 1075-2765 (ISSN-L)
- OpenAlex
- W1969921442
- Cited by
- 30
- References
- 6
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms. https://app.cochat.ai/papers/10.1097/mjt.0b013e31804c7292
- The paper
- Barkin, R. L. (2007). Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e31804c7292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.